Combined oral contraceptive use before the first birth and epithelial ovarian cancer risk.
Br J Cancer
; 116(2): 265-269, 2017 Jan 17.
Article
em En
| MEDLINE
| ID: mdl-27959890
ABSTRACT
BACKGROUND:
Combined oral contraceptive (COC) use reduces epithelial ovarian cancer (EOC) risk. However, little is known about risk with COC use before the first full-term pregnancy (FFTP).METHODS:
This Canadian population-based case-control study (2001-2012) included 854 invasive cases/2139 controls aged ⩾40 years who were parous and had information on COC use. We estimated odds ratios (aORs) and 95% confidence intervals (CI) adjusted for study site, age, parity, breastfeeding, age at FFTP, familial breast/ovarian cancer, tubal ligation, and body mass.RESULTS:
Among parous women, per year of COC use exclusively before the FFTP was associated with a 9% risk reduction (95% CI=0.86-0.96). Results were similar for high-grade serous and endometrioid/clear cell EOC. In contrast, per year of use exclusively after the FFTP was not associated with risk (aOR=0.98, 95% CI=0.95-1.02).CONCLUSIONS:
Combined oral contraceptive use before the FFTP may provide a risk reduction that remains for many years, informing possible prevention strategies.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Ovarianas
/
Ordem de Nascimento
/
Neoplasias Epiteliais e Glandulares
/
Anticoncepcionais Orais Combinados
Tipo de estudo:
Etiology_studies
/
Observational_studies
/
Risk_factors_studies
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
/
Pregnancy
País/Região como assunto:
America do norte
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article